Claims
- 1. A method for the treatment or prevention of a disorder selected from: single episodic major depressive disorder, recurrent major depressive disorder, dysthymic disorder, bipolar disorder and cyclothymic disorder in a human in need thereof which comprises administering to the human an effective amount of a polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine characterized by an X-ray powder diffraction pattern with key reflections at approximately: 12.0, 15.3, 16.6, 17.0, 17.6, 19.4, 20.0, 21.9, 23.6, 23.8, and 24.8° (2 theta) which is substantially free of a polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine characterized by an X-ray powder diffraction pattern with key reflections at approximately: 12.6, 16.7, 17.1, 17.2, 18.0, 20.1, 20.6, 21.1, 22.8, 23.9, and 24.8° (2 theta).
- 2. The method of claim 1 wherein the disorder is single episodic major depressive disorder.
- 3. The method of claim 1 wherein the disorder is recurrent major depressive disorder.
- 4. The method of claim 1 wherein the disorder is dysthymic disorder.
- 5. The method of claim 1 wherein the disorder is bipolar disorder.
- 6. The method of claim 1 wherein the disorder is bipolar I disorder.
- 7. The method of claim 1 wherein the disorder is bipolar II disorder.
- 8. The method of claim 1 wherein the disorder is cyclothymic disorder.
- 9. A method for the treatment or prevention of a disorder selected from: panic disorder with agoraphobia, panic disorder without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, stress disorder and generalised anxiety disorder in a human in need thereof which comprises administering to the human an effective amount of a polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine characterized by an X-ray powder diffraction pattern with key reflections at approximately: 12.0, 15.3, 16.6, 17.0, 17.6, 19.4, 20.0, 21.9, 23.6, 23.8, and 24.8° (2 theta) which is substantially free of a polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine characterized by an X-ray powder diffraction pattern with key reflections at approximately: 12.6, 16.7, 17.1, 17.2, 18.0, 20.1, 20.6, 21.1, 22.8, 23.9, and 24.8° (2 theta).
- 10. The method of claim 9 wherein the disorder is panic disorder with agoraphobia.
- 11. The method of claim 9 wherein the disorder is panic disorder without agoraphobia.
- 12. The method of claim 9 wherein the disorder is agoraphobia without history of panic disorder.
- 13. The method of claim 9 wherein the disorder is specific phobia.
- 14. The method of claim 9 wherein the disorder is social phobia.
- 15. The method of claim 9 wherein the disorder is obsessive-compulsive disorder.
- 16. The method of claim 9 wherein the disorder is stress disorder.
- 17. The method of claim 9 wherein the stress disorder is post-traumatic stress disorder.
- 18. The method of claim 9 wherein the stress disorder is acute stress disorder.
- 19. The method of claim 9 wherein the disorder is generalised anxiety disorder.
Parent Case Info
This is a division of application Ser. No. 09/458,168, filed Dec. 9, 1999, U.S. Pat. No. 6,229,010, which is a division of application Ser. No. 09/212,511, filed Dec. 15, 1998, now U.S. Pat. No. 6,096,742 and claims benefit of Provisional application Ser. No. 60/051,600, filed Jul. 2, 1997.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5719147 |
Dorn et al. |
Feb 1998 |
A |
Foreign Referenced Citations (2)
Number |
Date |
Country |
WO 9400440 |
Jun 1993 |
WO |
WO 9516679 |
Dec 1994 |
WO |
Non-Patent Literature Citations (1)
Entry |
Crocker, L. S. et al., “Polymorphism of a Pharmaceutical Compound”, Poster Presentation at 13th International Conf. on the Chem. of the Organic Solid State, Stony Brook, LI, NY, Jul. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/051600 |
Jul 1997 |
US |